Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IGM Biosciences, Inc. (IGMS : NSDQ)

• Company Description    IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences Inc. is based in Mountain View, California. Number of Employees: 149

• Price / Volume Information    Yesterday's Closing Price: $1.36 Daily Weekly Monthly 20 Day Moving Average: 1,136,021 shares Shares Outstanding: 59.78 (millions) Market Capitalization: $81.29 (millions) Beta: 0.48 52 Week High: $22.50 52 Week Low: $0.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.40% 8.19% 12 Week 11.48% -6.23% Year To Date -77.74% -79.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 325 EAST MIDDLEFIELD ROAD - MOUNTAIN VIEW,CA 94043 USA ph: 650-965-7873 fax: - None http://igmbio.com

• General Corporate Information    Officers Mary Beth Harler - Chief Executive Officer and Director Misbah Tahir - Chief Financial Officer Steven Weber - Senior Vice President; Corporate Controller Felix Baker - Director M. Kathleen Behrens - Director Peer Information IGM Biosciences, Inc. (CORR.) IGM Biosciences, Inc. (RSPI) IGM Biosciences, Inc. (CGXP) IGM Biosciences, Inc. (BGEN) IGM Biosciences, Inc. (GTBP) IGM Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 449585108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 59.78 Most Recent Split Date: (:1) Beta: 0.48 Market Capitalization: $81.29 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 38.98% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 116.47 Price/Cash Flow: - Price / Sales: 30.32 EPS Growth vs. Year Ago Period: -3.61% vs. Previous Quarter: -40.98% Sales Growth vs. Year Ago Period: 0.40% vs. Previous Quarter: 21.12% ROE 06/30/25 - - 03/31/25 - -317.97 12/31/24 - -190.68 ROA 06/30/25 - - 03/31/25 - -71.43 12/31/24 - -61.05 Current Ratio 06/30/25 - - 03/31/25 - 5.71 12/31/24 - 5.14 Quick Ratio 06/30/25 - - 03/31/25 - 5.71 12/31/24 - 5.14 Operating Margin 06/30/25 - - 03/31/25 - -7,417.79 12/31/24 - -7,308.51 Net Margin 06/30/25 - - 03/31/25 - -7,417.79 12/31/24 - -7,308.51 Pre-Tax Margin 06/30/25 - - 03/31/25 - -7,417.79 12/31/24 - -7,308.51 Book Value 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.82 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©